The June 29 Deadline: What the FDA's 503B Comment Period Means for Your GLP-1 Prescription

The FDA is 11 days from closing public comments on a proposal that would permanently end large-scale GLP-1 compounding. Here's what you need to know — and what you can do.

What's at Stake

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. This is the regulatory mechanism that has allowed outsourcing facilities to compound these medications at scale. If finalized, 503B outsourcing facilities will be permanently barred from compounding GLP-1 drugs — regardless of future shortages, pricing, or access concerns.

The public comment period closes on June 29, 2026. After that, the FDA reviews submissions and issues a final determination. Industry analysts expect the exclusion to be finalized by Q3 2026.

What the FDA Is Saying

The FDA's position is clear: there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk drug substances when FDA-approved versions are commercially available. FDA Commissioner Marty Makary stated directly: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."

The agency explicitly rejected affordability and insurance access as constituting clinical need. The legal framework under section 503B of the FD&C Act defines clinical need as a medical or scientific justification — not an economic one.

The FDA also cited safety data: more than 455 adverse event reports linked to compounded semaglutide and over 320 reports associated with compounded tirzepatide as of early 2025. Many involved dosing errors from patients self-administering incorrect doses from multidose vials.

What You Can Do Before June 29

Submit a Public Comment

The FDA accepts public comments through federal docket 2026-08552 on regulations.gov. Individual patient comments matter — they're part of the administrative record that the FDA must address in its final determination.

Effective comments focus on personal clinical experience: Did compounded GLP-1 medication address a specific medical need that branded products couldn't? Did your prescriber select compounding for a clinical reason (dosing customization, allergen avoidance, format preference)? Did the cost of branded medication prevent you from accessing treatment for a diagnosed condition?

Comments about pricing alone are unlikely to influence the outcome given the FDA's stated position that affordability doesn't constitute clinical need. But comments documenting specific clinical scenarios where compounding was medically necessary carry weight.

What Happens After June 29

The FDA reviews all submitted comments, addresses significant points in its response, and issues a final rule. The timeline is typically 60–120 days after the comment period closes, which means a final determination in Q3 or early Q4 2026.

Organizations including the National Community Pharmacists Association and the Alliance for Pharmacy Compounding are expected to file substantial comments. Legal challenges through the federal courts are likely regardless of the outcome — litigation over FDA's shortage authority is already active in the 5th Circuit.

What You Should Do Right Now

Don't wait for the final rule. If you're currently on compounded GLP-1 medication, start planning your transition now. Ask your provider whether they use 503A or 503B pharmacies. If 503B, ask about their transition plan. Research brand-name pricing through NovoCare (Wegovy) or LillyDirect (Zepbound). Consider providers who already offer both compounded and brand-name options.